Switch theme
Sign up to access all valuation multiples
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.
1890
4.1K+
LTM Revenue $2.1B
LTM EBITDA $440M
$3.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Santen Pharmaceutical has a last 12-month revenue (LTM) of $2.1B and a last 12-month EBITDA of $440M.
In the most recent fiscal year, Santen Pharmaceutical achieved revenue of $2.1B and an EBITDA of $348M.
Santen Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Santen Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $440M | XXX | $348M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $321M | XXX | $264M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $247M | XXX | $183M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Santen Pharmaceutical's stock price is JPY 1603 (or $11).
Santen Pharmaceutical has current market cap of JPY 547B (or $3.8B), and EV of JPY 453B (or $3.1B).
See Santen Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.1B | $3.8B | XXX | XXX | XXX | XXX | $0.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Santen Pharmaceutical has market cap of $3.8B and EV of $3.1B.
Santen Pharmaceutical's trades at 1.5x EV/Revenue multiple, and 11.0x EV/EBITDA.
Equity research analysts estimate Santen Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Santen Pharmaceutical has a P/E ratio of 15.2x.
See valuation multiples for Santen Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.8B | XXX | $3.8B | XXX | XXX | XXX |
| EV (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 7.1x | XXX | 11.0x | XXX | XXX | XXX |
| EV/EBIT | 9.7x | XXX | 16.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.2x | XXX | 33.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 9.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSanten Pharmaceutical's last 12 month revenue growth is 0%
Santen Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Santen Pharmaceutical's rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Santen Pharmaceutical's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Santen Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | 27% | XXX | XXX | XXX |
| Rule of 40 | 14% | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Santen Pharmaceutical acquired XXX companies to date.
Last acquisition by Santen Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Santen Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Santen Pharmaceutical founded? | Santen Pharmaceutical was founded in 1890. |
| Where is Santen Pharmaceutical headquartered? | Santen Pharmaceutical is headquartered in Japan. |
| How many employees does Santen Pharmaceutical have? | As of today, Santen Pharmaceutical has 4.1K+ employees. |
| Who is the CEO of Santen Pharmaceutical? | Santen Pharmaceutical's CEO is Mr. Takeshi Ito. |
| Is Santen Pharmaceutical publicy listed? | Yes, Santen Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of Santen Pharmaceutical? | Santen Pharmaceutical trades under 4536 ticker. |
| When did Santen Pharmaceutical go public? | Santen Pharmaceutical went public in 1964. |
| Who are competitors of Santen Pharmaceutical? | Similar companies to Santen Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Santen Pharmaceutical? | Santen Pharmaceutical's current market cap is $3.8B |
| What is the current revenue of Santen Pharmaceutical? | Santen Pharmaceutical's last 12 months revenue is $2.1B. |
| What is the current revenue growth of Santen Pharmaceutical? | Santen Pharmaceutical revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Santen Pharmaceutical? | Current revenue multiple of Santen Pharmaceutical is 1.5x. |
| Is Santen Pharmaceutical profitable? | Yes, Santen Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Santen Pharmaceutical? | Santen Pharmaceutical's last 12 months EBITDA is $440M. |
| What is Santen Pharmaceutical's EBITDA margin? | Santen Pharmaceutical's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Santen Pharmaceutical? | Current EBITDA multiple of Santen Pharmaceutical is 7.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
